August 15, 2024
Revolutionary AI and Brain Implants Restore ALS Patient’s Voice
ALS, brain-computer interface, AI, speech restoration, brain implants, medical breakthrough
Arrowhead Shifts Focus to Obesity Development After Heart Disease Drug Clearance
Arrowhead, obesity development, heart disease drug, biotech, pharmaceuticals, clinical-stage candidates, preclinical assets
Incyte and Syndax Secure FDA Approval for Niktimvo, a Breakthrough Treatment for Chronic Graft-Versus-Host Disease
Incyte, Syndax, Niktimvo, FDA approval, graft-versus-host disease, GVHD, axatilimab-csfr, chronic GVHD, allogeneic stem cell transplant
Mpox Outbreak in Africa: Siga’s Tpoxx Antiviral Falls Short in Congo Study
mpox, Tpoxx, antiviral, Congo study, Africa outbreak, Siga, tecovirimat
Bavarian Nordic Returns to the Spotlight as Mpox Outbreak Reaches Emergency State
Bavarian Nordic, mpox outbreak, emergency state, vaccine production, WHO declaration, public health emergency
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
Evotec Announces Restructuring Plan Amid Research Spending Slowdown
Evotec, layoffs, restructuring, research spending slowdown, gene therapy, biopharma
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Gilead’s $4.3B Acquisition of CymaBay Yields FDA Approval for Autoimmune Liver Disease Treatment
Gilead Sciences, CymaBay, FDA Approval, Autoimmune Liver Disease, Seladelpar, Primary Biliary Cholangitis